SCHEMBL6292842

SCHEMBL6292842

Cn1c(=O)c(Cc2ccc(F)c(F)c2)cc2nc(C(=O)NCc3ccccc3)oc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.42
POLB P06746 3/20 0.41
TP53 P04637 1/20 0.41
THRB P10828 1/20 0.41
CACNA1G O43497 2/20 0.40
CACNA1H O95180 2/20 0.40
CACNA1I Q9P0X4 2/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
MAPT P10636 1/20 0.39
NAMPT P43490 1/20 0.39
S1PR3 Q99500 1/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
RAB9A P51151 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
KLKB1 P03952 1/20 0.39
KLK1 P06870 1/20 0.39
HMGCR P04035 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6292153 0.87 EGFR (0.45) PTGER4TP53SMN1; SMN2MAPTALDH1A1
SCHEMBL6288790 0.81 MAOB (0.48) PTGER4CACNA1GCACNA1HCACNA1ISMN1; SMN2
SCHEMBL6289370 0.81 MMP13 (0.46) PTGER4MAPTNAMPTKLKB1KLK1
SCHEMBL6700366 0.79 S1PR3 (0.44) PTGER4CACNA1GCACNA1HCACNA1IS1PR3
SCHEMBL6292190 0.77 MAPT (0.45) CACNA1GCACNA1HCACNA1ISMN1; SMN2MAPT
SCHEMBL6477648 0.76 POLB (0.42) PTGER4POLBTP53THRBCACNA1G
SCHEMBL6292735 0.76 MMP13 (0.35) S1PR3MAPK1MMP13
SCHEMBL6289340 0.75 MAPK14 (0.39) POLBTP53CACNA1GCACNA1HCACNA1I
SCHEMBL6348866 0.73 MMP13 (0.51) LMNAMMP13
SCHEMBL6696562 0.72 PTGER4 (0.42) PTGER4CACNA1GCACNA1HCACNA1IS1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US disclosed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US disclosed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 PTGER4 1598/4885POLB 2737/4885TP53 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.